Business Context and Reporting Period
This Form 6-K filing by Can-Fite Biopharma Ltd. covers the month of December 2021. The registrant is a foreign private issuer based in Petach-Tikva, Israel, and files annual reports on Form 20-F. The filing primarily serves to incorporate a press release dated December 20, 2021, regarding clinical trial progress.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is a current event disclosure rather than a financial statement.
Material Changes
The material change reported is a clinical development milestone. A liver cancer patient treated with the company's drug candidate, Namodenoson, cleared all cancer lesions during an open-label extension of a Phase II study.
Guidance, Outlook, and Risks
The filing incorporates a press release detailing the positive clinical outcome for Namodenoson. No specific financial guidance, management outlook, or discussion of risks and contingencies is included in the text of this specific Form 6-K.
Investor Verification Points
- Verify the full details of the press release attached as Exhibit 99.1 regarding the liver cancer patient's response to Namodenoson.
- Confirm the status of the open-label extension of the Phase II study mentioned in the filing.
- Review the company's most recent Form 20-F for actual financial data, as this filing contains no financial metrics.